deltatrials
Terminated PHASE2 INTERVENTIONAL 2-arm NCT03007719

Functional Imaging of T-Cell Activation With [18F]F-AraG in Urothelial Carcinoma Patients Receiving Neoadjuvant Therapy or Patients With Cancer Receiving Standard of Care Anti-PD-1/L1

Sponsor: CellSight Technologies, Inc.

Conditions Bladder Cancer
Interventions Fluorine F 18 Ara-G Magnetic Resonance Imaging Positron Emission Tomography
Updated 16 times since 2017 Last updated: Jan 10, 2020 Started: Mar 7, 2017 Primary completion: Jan 11, 2019 Completion: Jan 11, 2019
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Low Accrual

Other terminated trials from CellSight Technologies, Inc.

More terminations from CellSight Technologies, Inc.

Other Bladder Cancer trials with similar outcome

Browse all Bladder Cancer trials

This PHASE2 trial investigates Bladder Cancer and is currently terminated or withdrawn. CellSight Technologies, Inc. leads this study, which shows 16 recorded versions since 2017 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~May 2017 · 3 months · monthly snapshot~May 2017 – ~Jun 2017 · 31 days · monthly snapshot~Jun 2017 – ~Aug 2017 · 2 months · monthly snapshot~Aug 2017 – ~Mar 2018 · 7 months · monthly snapshot~Mar 2018 – ~Jun 2018 · 3 months · monthly snapshot~Jun 2018 – ~Feb 2019 · 8 months · monthly snapshot~Feb 2019 – ~Sep 2019 · 7 months · monthly snapshot~Sep 2019 – ~Feb 2020 · 5 months · monthly snapshot~Feb 2020 – ~Jan 2021 · 11 months · monthly snapshot~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshot~Dec 2021 – ~Dec 2022 · 12 months · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Jul 2024 · 18 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

16 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  3. Jan 2023 — Jul 2024 [monthly]

    Terminated PHASE2

  4. Dec 2022 — Jan 2023 [monthly]

    Terminated PHASE2

  5. Dec 2021 — Dec 2022 [monthly]

    Terminated PHASE2

▶ Show 11 earlier versions

  1. Jan 2021 — Dec 2021 [monthly]

    Terminated PHASE2

  2. Feb 2020 — Jan 2021 [monthly]

    Terminated PHASE2

    Status: Active Not Recruiting → Terminated

  3. Sep 2019 — Feb 2020 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  4. Feb 2019 — Sep 2019 [monthly]

    Recruiting PHASE2

  5. Jun 2018 — Feb 2019 [monthly]

    Recruiting PHASE2

  6. Mar 2018 — Jun 2018 [monthly]

    Recruiting PHASE2

  7. Aug 2017 — Mar 2018 [monthly]

    Recruiting PHASE2

    Phase: NA → PHASE2

  8. Jun 2017 — Aug 2017 [monthly]

    Recruiting NA

  9. May 2017 — Jun 2017 [monthly]

    Recruiting NA

    Status: Not Yet Recruiting → Recruiting

  10. Feb 2017 — May 2017 [monthly]

    Not Yet Recruiting NA

  11. Jan 2017 — Feb 2017 [monthly]

    Not Yet Recruiting NA

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • CellSight Technologies, Inc.
  • Lawrence Fong
Data source: University of California, San Francisco

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations